Articles eligible for this systematic review
| First author, YOP | Country | Sample size | Disease severity | ATT | Age | Female (%) | Follow-up |
| Randomised controlled trials | |||||||
| Cassar, 200645 | UK | 67 | R 1–3 w EVR | A w C or PLB | Mn 66 (R: 43–80) | 15 (22) | 1 M |
| Haile, 202232 | Sweden | 105 | R 1–3 w EVR/SVR | Any ATT | Md 72 (IQR: 69–77) | 54 (52) | 1.5 Y |
| Hess, 202230 | Multiple | 6564 | R 1–6 w EVR/SVR | ASA w PLB or DOAC | Mn 68 (IQR: 60–76) | 1704 (26) | Md 28 M (IQR: 22–34) |
| Jivegård, 200548 | Sweden | 281 | R 4–6 | ASA w PLB or LMWH | Mn 74 (SD:9) | 126 (45) | 3 M |
| Qvist, 201931 | Denmark | 2051 | R 0–6 w/o EVR/SVR | Any ATT | Mn 70 (SD: 2.9) | 0 (0) | 5 Y |
| Weissler, 202229 | Multiple | 13 842 | R 1–6 w/o EVR/SVR | C or T | Mn 67 (IQR: 59–75) | 3884 (28) | 30 M (up to 42 M) |
| Prospective trials | |||||||
| Ferreira, 201046 | Spain | 194 | NR | Any APT | Mn 64 (SD: 11.2) | 43 (22) | 1 Y |
| Kremers, 2023 49 | Netherlands | 246 | R 1–4 | Any APT | Mn 69 (SD: 9.2) | 105 (43) | 1 Y |
| Retrospective studies | |||||||
| Halle, 201736 | USA | 100 | R 1–6 w/o EVR/SVR | Any APT | Mn 64 (SD: 9.5) | 42 (42) | NR |
| Wawruch, 202133 | Slovak Republic | 9178 | R 0–6 w/o EVR/SVR | Any APT | Mn 75 | 5285 (58) | 5 Y |
| Total | 32 628 | 11 258 (35) | |||||
±, SD deviation; (), percentage; A, acetylsalicylic acid; APT, antiplatelet therapy; ATT, antithrombotic therapy; C, clopidogrel; DOAC, direct-acting oral anticoagulant; EVR, endovascular revascularisation; LMWH, low molecule weight heparin; M, months; Md, median; Mn, mean; NR, not reported; PLB, placebo; R, Rutherford classification; R, range; SVR, surgical/open revascularisation; w, with; w/o, with or without; Y, years; YOP, year of publication.